Research on Relationship of HIF-1 Signaling Pathway and Postmenstrual Osteoporosis
Abstract
Exploring the role of hypoxia-induceibal factor-1 (HIF-1) signaling pathway in postmenstrual osteoporosis (PMOP) and how to play a role in PMOP. MethodsSixty C57BL/6J female mouse were randomly divided into 4 groups: sham-operation group (A group), ovariectomized PMOP group (B group), HIF-1 alpha inhibitor 2-methoxy estradiol (2ME2) treatment group(D group) and solvent control group(C group), 15 mice in each group. There months after modeling, the metabolism product of mouse bone tissue including serum propeptide of typeⅠ procollagen (PINP), C-terminal telopeptide-Ⅰ (CTX-1) and serum estrogen were quantified by enzyme-linked immunosorbent assay (ELISA). Changes of bone structure were observed on HE stained tissue sections. Regulation products of HIF-1 signaling pathway including HIF-1α, HIF-1β, specific prolyl hydroxylases (PHD), Hipple-Lindau tumor suppressor protein (VHL), and factor inhibiting HIF (FIH) were measured by immuno-histochenmistry staining. Osteoclasts derived from OVX-mice were treated with inhibitors of extracellular regulated protein kinases (ERK), protein kinase B (Akt) and nuclear factor kappa B (NF-κB) signaling pathways. HIF-1α expression were detected by Western blot to obtain a rudimentary knowledge of possible mechanism of up-regulation of HIF-1α in osteoclasts of postmenospausal osteoporosis. ResultsMetabolism product of mouse bone tissue of B group were higher than A group ( P<0.001). The positive expression of HIF-1-alpha protein was found in osteoclasts, and the expression of HIF-1-alpha protein in bone marrow region was higher than that in A group ( P<0.001), while the change od HIF-1β, PHD, VHL, and FIH were not obviously. After the HIF-1α inhibitor treatment, markers of bone resorption of bone metabolism in ovariectomized mice reduced and the osteoporosis get greatly relieved ( P<0.001). HIF-1α expression was down-regulated in osteoclasts of OVX-mice after treated with inhibitors of ERK, Akt and NF-κB signaling pathways ( P<0.05). ConclusionHIF-1 signaling pathway get involved in the pathological evolution of osteoporosis after menopause, and inhibition of HIF-1 can significantly improve the severity of osteoporosis after menopause. ERK, Akt and NF-κB signaling pathways may involve in the up-regulation of HIF-1 signaling pathway in osteoclasts of PMOP.
Keywords: Ovariectomy, Osteoporosis, HIF-1α, Osteoclast
Full Text:
PDFReferences
WANG Y, WAN C, DENG L, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest, 2007 , 117 ( 6 ); 1616-1626.
KNOWLES HJ, CLETON-JANSEN AM, KORSCHING E, et al. Hypoxia-inducible factor regulates osteoclast-mediated bone resorption; role of angiopoietin-like 4. FASEB J ,2010, 24(12):4648-4659.
ZHOU J, BRUNE B. Cytokines and hormones in the regulation of hypoxia inducible factor-lalpha ( HIF-lalpha). Cardiovasc Hematol Agents Med Chem,2006,4(3): 189-197.
RACHNER TD, KHOSLA S, HOFBAUER LC. Osteoporosis; now and the future. Lancet ,2011 ,377(9773); 1276-1287.
MANSFIELD KD. GUZY RD, PAN Y, et al. Mitochondrial dysfunction resulting from loss of cytochrome с impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab,2005,1(6) :393-399.
REILING JH, SABATINI DM. Stress and mTORture signaling. Oncogene,2006,25(48) ; 6373-6383.
SONENBERG N, HINNEBUSCH AG. New modes of translational control in development, behavior, and disease. Mol Cell,2007,28(5) ;721-729.
RUVINSKY I, SHARON N, LERER T, et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev,2005,19(18):2199-2211.
FLLJGEL D, GORLACH A, MICHIELSC, et al. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1 alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol,2007,27(9):3253-3265.
TANG TT, LASKY LA. The forkhead transcription factor F0X04 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism. J Biol Chem,2003,278(32):30125-30135.
EMERLING BM, WEINBERG F, LIU JL, et al. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (F()X()3a). Proc Natl Acad Sci U S A, 2008, 105 ( 7); 2622-2627.
GAO Y, QIAN WP, DARK K. et al. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA, 2004, 101(47); 16618- 16623.
SANYAL A, HOEY KA, MODDER UI. Et al. Regulation of bone turnover by sex steroids in men. J Bone Miner Res, 2008,23(5):705-714.
IQBAL J, SUN L, KUMAR TR, et al. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A,2006,103(40): 14925-14930.
SCHAIBLE EV, WINDSCHUGL J, BOBKIEWICZ W, et al. 2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIP-1 ct response after traumatic brain injury in mice. J Neurochem,2014 ,129(6); 940-954.
STUBELIUS A, ANDREASSON E, KARLSSON A, et al. Role of 2-methoxyestradiol as inhibitor of arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis. Clin Immunol,2011 ,140( 1) :37-46.
KNOWLES HJ, ATHANASOU NA. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol, 2008, 215 (1) ; 56-66.
KNOWLES HJ, ATHANASOU NA. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol. 2008. 215 (1): 56-66.
INDO Y, TAKESHITA S, ISHII KA, et al. Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res,2013,28( 11):2392-2399.
MIYAUCHI Y, SATO Y. KOBAYASHI T, et al. HIFla is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A, 2013,110(41);16568-16573.
KNOWLES HJ. ATHANASOU NA. Acute hypoxia and osteoclast activity; a balance between enhanced resorption and increased apoptosis. J Pat hoi, 2009,218( 2); 256-264.
SCOTT A, HIGDON K, TUCCI M, et al. The prevention of osteoporotic progression by means of steroid loaded TCPL drug delivery systems. Biomed Sci Instrum. 2001 ,37 ; 13-18.
YEN ML, SU JL, CHIEN CL, et al. Diosgenin induces hypoxia-inducible factor-1 activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts. Mol Pharmacol,2005,68(4 ): 1061-1073.
Refbacks
- There are currently no refbacks.



